UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Position in Nurix Therapeutics, Inc. $NRIX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 14.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 135,104 shares of the company’s stock after selling 22,246 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Nurix Therapeutics were worth $3,278,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Larson Financial Group LLC increased its position in Nurix Therapeutics by 339.0% during the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock worth $29,000 after purchasing an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management purchased a new position in Nurix Therapeutics in the fourth quarter valued at approximately $31,000. Caitong International Asset Management Co. Ltd acquired a new position in Nurix Therapeutics during the fourth quarter valued at approximately $33,000. KBC Group NV acquired a new position in Nurix Therapeutics during the first quarter valued at approximately $34,000. Finally, Avalon Trust Co purchased a new stake in Nurix Therapeutics during the second quarter worth approximately $64,000.

Nurix Therapeutics Stock Down 1.7%

Shares of NASDAQ:NRIX opened at $25.81 on Friday. Nurix Therapeutics, Inc. has a 52-week low of $8.19 and a 52-week high of $28.23. The company has a 50 day moving average of $25.07 and a two-hundred day moving average of $19.65. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -7.48 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last posted its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The firm had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $15.29 million. On average, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.69 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44. Following the sale, the insider owned 117,227 shares of the company’s stock, valued at $2,985,771.69. The trade was a 1.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Hans van Houte sold 4,761 shares of the business’s stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the transaction, the chief financial officer owned 40,166 shares in the company, valued at $978,443.76. This represents a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 26,766 shares of company stock valued at $626,343. Company insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on NRIX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Friday, July 17th. Jefferies Financial Group upped their price target on shares of Nurix Therapeutics from $41.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, June 8th. Needham & Company LLC reiterated a “buy” rating and issued a $34.00 price target on shares of Nurix Therapeutics in a report on Tuesday, August 4th. Morgan Stanley increased their price target on Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, July 28th. Finally, Stifel Nicolaus raised their price objective on Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.21.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.